OCRX—I’m going out on a limb and predicting a 40%+ increase in the share price if the DSMB decides to continue the STOP-HE phase-2b study with no increase in enrollment size (a trial-design feature for which 0.01 of alpha is being spent).
Anyone agree/disagree?
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.